See relevant content for Battelleventures.com
Investment Type: Venture Capital
Mentions in press and media 10
| Date | Title | Description | Source |
| 18.12.2012 | Proterro Closes $3.5M Financing | Proterro, Inc., an Ewing, NJ-based company making sugar instead of extracting it from crops, closed ... | finsmes.co... |
| 06.08.2012 | Minimally invasive heart surgery device gets follow-on inves... | In addition to Ben Franklin Technology Partners of Northeastern Pennsylvania, other investors have i... | medcitynew... |
| 16.07.2012 | Migraine patch application resubmitted for FDA approval | Jane Hollingsworth, NuPathe’s CEO, said she expects a six-month review by the FDA. “With the additi... | medcitynew... |
| 10.05.2012 | Minimally invasive cardiac surgery closure device to cut rec... | Micro Interventional Devices’ lead device, Permaseal ,uses a sutureless technology to repair the acc... | medcitynew... |
| 15.11.2011 | NuPathe to resubmit migraine patch for approval in 2012 | Migraine headaches affect about 31 million adults in the United States. Symptoms include moderate to... | medcitynew... |
| 18.09.2009 | Friday Q&A: Jane Hollingsworth of NuPathe on Zelrix, mig... | Updated 9/18/09 @ 2:42 p.m. Name in title When Jane Hollingsworth takes a pill to help fight a head... | technical.... |
| - | NuPathe to resubmit migraine patch for approval in 2012 | NuPathe (NASDAQ: PATH) said it will resubmit a new drug application for its transdermal migraine pat... | medcitynew... |
| - | Minimally invasive heart surgery device gets follow-on inves... | A company with a suture-less closure device for heart surgery procedures intended to reduce blood lo... | medcitynew... |
| - | Migraine patch application resubmitted for FDA approval | NuPathe (NASDAQ:PATH), a biopharmaceutical company, has resubmitted a new drug application for its m... | medcitynew... |
| - | Minimally invasive cardiac surgery closure device to cut rec... | As the trend toward minimally invasive cardiac surgery grows, a cardiac medical device startup has d... | medcitynew... |